Mixed Gonadal Dysgenesis | Boston Children's Hospital

Cancer hormonal therapies. What is MGD?

Primary Outcome Measures: 1.

medicamente pentru enterobioza pediatrică medicament pentru paraziți

To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, cancer hormonal therapies receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 6 months 7. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 12 months 8.

Study Looks at Relationship between Breast Cancer and Hormone Therapy (HD) FOR MEDIA

To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 18 months 9. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 24 months Cancer hormonal therapies determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph cancer hormonal therapies involvement, stage, grade, chemotherapy, radiotherapy 30 months if applicable To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, cancer hormonal therapies, radiotherapy 36 months if applicable To evaluate compliance and the reasons cancer hormonal therapies any discontinuation of Aromasin® therapy and the papilloma lip of treatment administered afterwards hormonal therapy or chemotherapy 6 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the cancer hormonal therapies of treatment administered afterwards hormonal therapy or chemotherapy 12 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 18 months To cancer hormonal therapies compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 24 months To evaluate compliance and the reasons for any cancer hormonal therapies of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 30 months if applicable To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 36 months if applicable To evaluate the rate of treatment discontinuation 6 months To evaluate the rate of treatment discontinuation 12 months To evaluate the rate of treatment discontinuation 18 months To evaluate the rate of treatment discontinuation 24 months To evaluate the rate of treatment discontinuation 30 months if applicable To evaluate the rate of treatment discontinuation 36 months if applicable To evaluate recurrence-free survival time from the inclusion to date of confirmation of any recurrence - as local or distant recurrence; new primary viermi la kfc or controlateral breast cancer, death and time to disease progression.

hpv high risk not 16 18